Xenorhabdus khoisanae SB10 produces Lys-rich PAX lipopeptides and a Xenocoumacin in its antimicrobial complex

J. Dreyer, M. Rautenbach, E. Booysen, A. D. van Staden, S. M. Deane and L. M. T. Dicks

Abstract

Background: Xenorhabdus spp. live in close symbiosis with nematodes of the Steinernema genus. Steinernema nematodes infect an insect larva and release their symbionts into the haemocoel of the insect. Once released into the haemocoel, the bacteria produce bioactive compounds to create a semi-exclusive environment by inhibiting the growth of bacteria, yeasts and molds. The antimicrobial compounds thus far identified are xenocoumacins, xenortides, xenorhabdins, indole derivatives, xenoamicins, bicornutin and a number of antimicrobial peptides. The latter may be linear peptides such as the bacteriocins xenocin and xenorhabdicin, rhabdopeptides and cabanillasin, or cyclic, such as PAX lipopeptides, taxillids, xenobactin and szentiamide. Thus far, production of antimicrobial compounds have been reported for Xenorhabdus nematophilia, Xenorhabdus budapestensis, Xenorhabdus cabanillasii, Xenorhabdus khoisanae, Xenorhabdus szentirmaii, Xenorhabdus doucetiae, Xenorhabdus mauleonii, Xenorhabdus indica and Xenorhabdus bovienii. Here we describe, for the first time, PAX lipopeptides and xenocoumacin 2 produced by Xenorhabdus khoisanae. These compounds were identified using ultraperformance liquid chromatography, linked to high resolution electrospray ionisation mass spectrometry and tandem mass spectrometry.

Results: Cell-free supernatants of X. khoisanae SB10 were heat stable and active against Bacillus subtilis subsp. subtilis, Escherichia coli and Candida albicans. Five lysine-rich lipopeptides from the PAX group were identified in HPLC fractions, with PAX1' and PAX7 present in the highest concentrations. Three novel PAX7 peptides with putative enoyl modifications and two linear analogues of PAX1' were also detected. A small antibiotic compound, yellow in colour and $\lambda_{max}$ of 314 nm, was recovered from the HPLC fractions and identified as xenocoumacin 2. The PAX lipopeptides and xenocoumacin 2 correlated with the genes and gene clusters in the genome of X. khoisanae SB10.

Conclusion: With UPLC-MS and MS$^*$ analyses of compounds in the antimicrobial complex of X. khoisanae SB10, a number of PAX peptides and a xenocoumacin were identified. The combination of pure PAX1' peptide with xenocoumacin 2 resulted in high antimicrobial activity. Many of the fractions did, however, contain labile compounds and some fractions were difficult to resolve. It is thus possible that strain SB10 may produce more antimicrobial compounds than reported here, as suggested by the APE Ec biosynthetic complex. Further research is required to develop these broad-spectrum antimicrobial compounds into drugs that may be used in the fight against microbial infections.

Keywords: Xenorhabdus khoisanae, Antimicrobial complex, Lys-rich PAX lipopeptides, Xenocoumacin, Mass spectrometric analysis
Background

Xenorhabdus bacteria are in a species-specific association with Steinernema nematodes, i.e. a specific Steinernema sp. is associated with a specific Xenorhabdus sp. [1]. At the beginning of the Xenorhabdus-Steinernema life cycle, nematodes in the infective juvenile phase infect the insect host by entering the mouth, anus or respiratory spiracles [2]. Once inside the insect, the nematodes release the symbiotic bacteria by defecation. Steinernema nematodes produce proteins that suppress the insect’s immune response, which allows Xenorhabdus to multiply [3]. The release of exoenzymes and toxins by both mutualists leads to septicaemia and the insect dies within 24 to 48 h after infection [4–6]. Nematodes reproduce sexually by going through phases J1 to J4 until resources are depleted, after which they return to the infective juvenile state, acquire symbionts and leave the cadaver in search of a new host.

During the nematode life cycle, Xenorhabdus spp. produce various compounds to create a semi-exclusive environment and prevent colonisation of the host (insect) by other microorganisms [7]. Dutky [8] was the first to suggest that Xenorhabdus produce antimicrobial compounds. However, interest in these antimicrobial compounds only gained momentum 22 years later [9]. Numerous bioactive compounds have since then been detected in the cell-free supernatants of Xenorhabdus spp., including broad-spectrum compounds with activity against bacteria, fungi, insects, nematodes, protists and cancer cells. These compounds range from being small metabolites such as aryl polyenes [39]. Identification of the four modules coding for the PAX synthetase complex in the genome of X. khoisanae SB10 revealed the presence of the xenocoumacin biosynthetic gene cluster and an APE Ec gene cluster (Fig. 1). The APE Ec gene cluster is widely distributed amongst prokaryotes and is related to secondary metabolites such as aryl polyenes [39].

Results and discussion

Xenorhabdus bacteria are known to produce various antimicrobial compounds, but it is a highly neglected antimicrobial source that has not been exploited to its full potential. Although many genes relevant to antimicrobial compound biosynthesis have been identified in Xenorhabdus spp., the isolation, purification, identification and characterisation of antimicrobial compounds have not been done for all species belonging to this genus. Our antiSMASH [38] analysis of the genome of X. khoisanae SB10 revealed the presence of the xenocoumacin biosynthetic gene cluster and an APE Ec gene cluster (Fig. 1). The APE Ec gene cluster is widely distributed amongst prokaryotes and is related to secondary metabolites such as aryl polyenes [39].

A detailed analysis utilising ESMS, UPLC-MS and MS² data on these fractions can be found in the Additional file 1 section.

The first chromatography of the SPC active fractions on 15 RPC resin by FPLC yielded fraction A1 with broad-spectrum antimicrobial activity (Fig. 2a). The SPC A1 fraction was shown to have broad-spectrum activity towards the four target organisms (B. subtilis, E. coli and C. albicans), as well as retaining activity after heating at 121 °C for 20 min (results not shown). The latter result indicated marked heat stability of the antimicrobial compounds and eliminated activity related to labile, or volatile compounds and proteins such as proteases. The A1 fraction was further separated with C18-HPLC into seven peaks (Fig. 2b). Fractions B, D and G showed strong UV
absorption (Fig. 2b), suggesting that they did not only contain PAX peptides, but also xenocoumacin and breakdown products. Antimicrobial activity was observed in fractions A to G (Fig. 2b) and is shown in Fig. 3. We first focused on the three major UV-absorbing fractions, B, D and G, as well as C and F (Fig. 2b), for further analysis using high resolution UPLC-MS and UPLC-MS² (or MS/MS) analyses (refer to Additional file 1 and Table 2).

The major UPLC-MS peak observed in fraction B contained a small compound with a yellow colour (absorption maximum at 314 nm) and a monoisotopic $M_r$ of 406.2104 (Fig. 4b and c, insert shows UV-spectrum). The UPLC-MS² analysis of the peak, containing its molecular ion with $m/z$ 407.2176 at 4.27 min, yielded six major ions (Fig. 5a). The compound was identified as xenocoumacin 2 (expected $m/z$ = 407.2182) based on the characteristic fragmentation pattern. The ion with $m/z$ 250.1428 (Fig. 5a) represents the benzopyran-1-one fragment (expected $m/z$ = 250.1443), while the ion with $m/z$ 158.0788 (Fig. 5a) correlates to the remaining fragment with pyrrolidine as R group (expected $m/z$ = 158.0817) [37]. Ions with $m/z$ 176.0699, 190.0849, 215.1058 and 232.1324 (Fig. 5b) are the hydration and dehydration products of the two main fragments with $m/z$ 158.0788 and 250.1428 (Fig. 5b). This identification of a xenocoumacin produced by X. khoisanae SB10, was supported by antiSMASH [39] results of 100% similarity between the genome of strain SB10 and the xenocoumacin biosynthetic gene cluster (refer to Fig. 1).

Fraction B also contained an earlier eluting peak at 2.90 min (refer to Fig. 4a) of a larger compound with $m/z$ 1052.7948 ($M_r$ = 1051.7870). The fragmentation pattern of the ion with $m/z$ 1052.7948 showed a neutral loss of 128.09 from the major fragments, which is indicative of the loss of multiple Lys-residues from a peptide chain. The majority of ions with a neutral fragment loss also had resultant dehydration products. This dehydration is the consequence of a fragmentation reaction at the C-terminal of a Lys residue that leads to cyclisation in which the amino group of the Lys side chain participates, similar to fragmentation reactions found for ornithine-containing peptides [40]. Ions with $m/z$ 129.1015 and 84.0799 also maps to Lys and its immoinium ion. The ion spectrum of $m/z$ 1052.7948 and proposed fragmentation pattern is presented in Fig. 6. From this spectrum we were able to map the sequence to a Lys-rich lipopeptide from the PAX peptide group. This particular peptide was identified as PAX1’ with the R group as (3R)-3-hydroxytetradecanoyl coupled to Gly-Lys2-cyclo(Lys4) with an expected $M_r$ of 1051.7845 (refer to Fig. 6 for structure). Although fraction B did not show

---

**Table 1** Identification of the four modules coding for the PAX synthetase complex in the genome of X. khoisanae SB10

| Gene    | Protein product | Synthetase Protein | Presumed function | Position on Chromosome | Identity (%) | Positivity (%) | Origin          | Accession number   |
|---------|-----------------|--------------------|------------------|------------------------|--------------|---------------|----------------|-------------------|
| xcn1_2784 | PaxT            | XpsD               | ABC-transporter  | Node 4–50,691 to 52,328 | 76 (416/549) | 88 (487/549) | X. bovienii SS-2004 | CB181280.1        |
| xcn1_2783 | PaxA            | XpsA               | NRPS             | Node 4–52,788 to 56,036 | 62 (678/1098) | 76 (836/1098) | X. bovienii SS-2004 | CB181279.1        |
| xcn1_2782 | PaxB            | XpsB               | NRPS             | Node 4–66,118 to 76,893 | 63 (2265/3614) | 76 (2747/3614) | X. bovienii SS-2004 | CB181277.1        |
| xcn1_2781 | PaxC            | XpsB               | NRPS             | Node 4–56,079 to 66,107 | 69 (2307/3356) | 81 (2733/3356) | X. bovienii SS-2004 | CB181278.1        |
Table 2: Summary of the antimicrobial compounds in the three main absorbing fractions that were identified using UPLC-MS and UPLC-MS<sup>2</sup>. PAX peptide identities and names are from Fuchs et al. [32]

| Fraction | UPLC Rt (min) | m/z of major [M + H]<sup>+</sup> | Compound M<sub>r</sub> | Theoretical M<sub>r</sub>| Mass error (ppm) | Proposed compound identity |
|----------|--------------|-------------------------------|-----------------|----------------|-----------------|--------------------------------|
| B        | 4.27         | 407.2182                      | 406.2104        | 406.2104       | 0.0             | Xenocoumacin 2 (C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O<sub>6</sub>) |
|          | 2.93         | 1052.7948                     | 1051.7870       | 1051.7845      | 2.4             | PAX1* (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
| C        | 3.18         | 1078.8119                     | 1077.8041       | 1077.8001      | 3.7             | PAX7E1* (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
|          | 3.42         | 1070.8091                     | 1069.7921       | 1069.7951      | −2.8            | PAX11L* (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
| D        | 3.29         | 1066.8097                     | 1065.7965       | 1065.8001      | −3.4            | PAX3* (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
| F        | 3.47         | 1054.8115                     | 1053.8012       | 1053.8001      | 1.0             | PAX1L-DH* (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
|          | 3.32, 3.47   | 1080.8286                     | 1079.8191       | 1079.8158      | 3.1             | PAX7 (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
|          | 3.71         | 1078.8096                     | 1077.8002       | 1077.8001      | 0.1             | PAX7E2* (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
|          | 3.88         | 1078.8070                     | 1077.7979       | 1077.8001      | −2.0            | PAX7E3* (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
| G        | 2.51         | 1050.7723                     | 1049.7623       | 1049.7688      | −6.2            | PAX5 (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
|          | 2.90         | 1052.7936                     | 1051.7821       | 1051.7845      | 2.3             | PAX1* (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
|          | 3.57         | 1080.8280                     | 1079.8161       | 1079.8158      | 0.3             | PAX7 (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |
|          | 3.83         | 1106.8412                     | 1105.8294       | 1105.8314      | −1.8            | PAX8 (C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>)GK6 |

*Experimental monoisotopic M<sub>r</sub> of compound was calculated using the TOF transform or MaxEnt3 function in the MassLynx 4.01 software package.

<sup>a</sup>Theoretical monoisotopic M<sub>r</sub> of compound was calculated from accurate monoisotopic M<sub>r</sub> of Lys =128.09496 and Gly = 57.02146, and monoisotopic A of O = 15.99491; H = 1.0078250, N = 14.0030740 and C = 12.0000000.

<sup>b</sup>Mass error in parts per million (ppm) = 10<sup>6</sup>×(|M<sub>r</sub> (theoretical) - M<sub>r</sub> (experimental)|/ M<sub>r</sub> (theoretical)).

<sup>c</sup>Early elution of broad peak, fronting and tailing due to aggregation at high concentration.

<sup>d</sup>Possible identification as PAX peptides from peptide moiety fragments and accurate mass determination, E denotes an enoyl group, L denotes linear, DH correlated to a linear analogue of PAX1.

<sup>e</sup>Putative identification as PAX peptides from peptide moiety fragments and accurate mass determination.

*Putative identification as PAX peptides from peptide moiety fragments and accurate mass determination, E denotes an enoyl group, L denotes linear, DH correlated to a linear analogue of PAX1.

Refer to Additional file 1 for UPLC-MS, ESM5 and MS/MS data on all the compounds.

High activity against E. coli Xen 14, high activity was recorded against all other target strains when purified PAX1<sup>+</sup> and xenocoumacin were combined in a 1:1 ratio (Fig. 3). This result warrants further investigation to determine if the activity between PAX peptides and small water soluble xenocoumacins is synergistic.

With the identification of the PAX1<sup>+</sup> peptide there was a high probability of other PAX peptides in the HPLC fractions. In fraction C two more PAX peptides were found, namely a PAX peptide (m/z 1070.8091) which correlated to a linear analogue of PAX1<sup>+</sup> (denoted PAX1'L) and a novel PAX peptide from the A group at m/z 1078.8119, that correlated to a PAX7 with an enoyl group in the lipid chain, denoted PAX7E1. This putative identification was done from the accurate M<sub>r</sub> fragmentation pattern of the peptide moiety (refer to Additional file 1) and the fact that it eluted just before PAX7. This elution pattern correlated very well with that of PAX1<sup>+</sup> and its 7-enoyl analogue PAX5 (see discussion below and Table 2). As there is already this identified 7-enoyl analogue in the PAX group, it is possible PAX7E1 is also a 7-enoyl analogue. We were, however, not able to confirm the structure of the R group with our in-analysis MS<sup>2</sup> methodology, as the CID energy only released the lipid moiety and limited fragmentation was achieved.

Fraction D contained PAX3' (m/z 1066.8097) and fraction F contained PAX7 (m/z 1080.8286). This fraction also contained UV absorbing compounds (refer to Fig. 2) that are possibly the result of xenocoumacin breakdown (detected compounds with m/z 250.2162, 268.2263, 270.2425, 286.2369). The high PAX7 concentration in fraction F led to UPLC peak broadening, possibly due to the aggregation of this lipopeptide. Although PAX7 was the major compound in fraction F, this fraction also contained other PAX-like peptides. Two low abundance peptides with different elution times, but with the same m/z as PAX7E1 with a putative double bond (enoyl) in lipid chain, were observed at 3.71 and 3.88 min (m/z 1078.8096 and m/z 1078.8096, denoted PAX7E2 and PAX7E3). PAX7E2 displayed similar peptide chain fragments to that of PAX7 and PAX7E1, suggesting that the difference in elution time may or due to the position of the putative double bond in the lipid chain (refer to Additional file 1). PAX7E3 co-eluted with various compounds, so the fragmentation pattern was inconclusive although many similar Lys derived fragments were observed. Alternatively, it could be that PAX7E2 and PAX7E3 elutes later than PAX7E1 due to aggregation with PAX7 and other compounds, rather than structural differences. A peptide with m/z 1054.8090 co-eluted with the PAX7 peptide. From the accurate M<sub>r</sub> it was derived that this peptide could be a linear PAX1<sup>+</sup> without a hydroxyl-group (denoted PAX1'L-DH), but the structure remains unconfirmed due to the co-elution. Fraction G contained a number of PAX peptides, namely PAX5 (m/z 1050.7723), PAX1<sup>+</sup> (m/z 1052.7936), PAX7 (m/z 1080.8280) and PAX8 (m/z 1106.8412). The fact that the same PAX peptides eluted in more than one fraction is
possibly due to the formation of hetero-oligomers by the different lipopeptides, leading to elution at different acetonitrile concentrations during reverse phase chromatography. As in fraction D, fraction G also contained some UV absorbing compounds (refer to Fig. 2) that are possibly the result of xenocoumacin breakdown. Examples of the UPLC-MS chromatograms and spectra of the five most abundant PAX peptides are presented in Fig. 7. The primary structures of the known PAX peptides that were found in this study are given in Fig. 8. We were able to confirm the peptide sequence of most of the identified PAX peptides with our UPLC-MS procedure, except those that were found in very low concentrations. Similar fragment patterns to that depicted in Fig. 5 for PAXI' were observed for the PAX peptides discussed above (refer to Additional file 1). This discovery and identification of the PAX lipopeptides were supported by the identification of the four modules coding for the PAX synthetase complex in the genome of X. khoisanae by our tblastx study (refer to Table 1).

Conclusions

It was not surprising to discover the production of various antimicrobial compounds by X. khoisanae due to the Xenorhabdus-Steinernema-insect host tripartite interaction [1]. The known PAX peptides have only been isolated from X. nematophila, however, this is the first report of PAX peptides produced by X. khoisanae. PAX lipopeptides were first characterised by Gaulteri et al. [16] and to date 13 unique PAX peptides have been reported [34]. Our UPLC-MS and MS² analyses and identification of PAX peptides and compounds in the antimicrobial complex of X. khoisanae SB10 have not been exhaustive, because of the complexity of many fractions containing labile compounds or unresolved compounds. There are certainly more antimicrobial compounds to discover in this strain's natural antimicrobial complex in
future studies, such as other xenocoumacins, xenorhabdins and compounds from the aryl polylene group, as indicated by the detection of the APE Ec biosynthetic complex (refer to Fig. 1). Because we consistently found the PAX lipopeptides and xenocoumacin in all the X. khoisanae SB10 culture extracts, we focused in this study on these compounds. Possible metabolites and degradation products related to the xenocoumacins were observed in some fractions (D and G), but after in-depth analysis of all the chromatographic fractions using UPLC-MS only one intact xenocoumacin, namely xenocoumacin 2, was identified in fraction B. It is possible that other xenocoumacins were also produced, but that the more labile compounds were lost during purification in a highly acidic environment. We were, however, able to identify five known Lys-rich lipopeptides from the PAX A-group with PAX1' and PAX7 being the most abundant. We also discovered two putative linear PAX analogues, which could possibly be metabolic precursors of PAX1'. PAX7 could be related to the three unknown PAX peptides with the same M_r of 1077.80 but different retention on a reverse phase matrix. From their M_r fragmentation patterns and UPLC elution behaviour we putatively classified the three peptides as enoyl-derivatives of PAX7. We were, however, unable to confirm the R-group because of low abundance and co-elution, as well as limited fragmentation of the R-group in MS^2 mode.

This study is the first to identify both the PAX peptides and a xenocoumacin in the antimicrobial complex of a Xenorhabdus species, as well as the first study on the antimicrobial complex of the Southern African X. khoisanae SB10. This report also highlights the natural tendency of Xenorhabdus species to produce antimicrobial complexes consisting of small antibiotics and AMPs. With the rising antibiotic resistance it may be wise to consider combining AMPs and small antibiotics, mimicking Xenorhabdus-type antimicrobial complexes.

**Methods**

**Bacterial strains, growth media and growth conditions**

*Xenorhabdus khoisanae* SB10 was maintained on NBTA [41], consisting of nutrient agar supplemented with bromothymol blue (0.025%, w/v) and TTC (0.004%, w/v). Incubation was at 30 °C. *Bacillus subtilis* subsp. *subtilis* BD170, *Escherichia coli* Xen 14 and *Candida albicans* CAB 392 were used as targets in the testing for antimicrobial activity. The bacteria and yeast were incubated at 37 °C. Bacteria were cultured on Brain Heart Infusion agar (Biolab Diagnostics, Gauteng, South Africa) and *C. albicans* on Potato Dextrose Agar (PDA, Biolab Diagnostics).

**Isolation of antimicrobial compounds**

XAD-16 beads were activated by treating with 80% isopropanol containing 0.1% (v/v) TFA and added to TSB. After 30 min at 4 °C on an orbital shaker (100 rpm), the XAD-16 beads were removed and the medium autoclaved. *X. khoisanae* SB10 was inoculated into 5 ml untreated TSB and incubated at 26 °C for 24 h on a rotating wheel. The culture was added to 5 g activated XAD-16 beads, spread-plated onto XAD-16-treated TSB agar in petri dishes with a diameter of 135 mm and incubated at 26 °C for 96 h. Beads were collected from the plates and washed with sterile deionised water to remove the cells. Water was removed from beads by vacuum suction. The beads were washed with 150 mL 30% (v/v) ethanol for 15 min at 4 °C on an orbital shaker (100 rpm). Ethanol was removed by vacuum suction and the beads were washed with sterile deionised water. Amphipathic
compounds were liberated from the beads, using 70% (v/v) isopropanol containing 0.1% (v/v) TFA (isopropanol-TFA). The eluent was filtered through a 0.45 μM cellulose nitrate filter and the isopropanol removed by using a rotary evaporator (RotaVapor® R-114, Büchi).

**Purification of antimicrobial compounds**

The concentrated eluent was subjected to reverse phase chromatography on a 10 ml Sep-Pak C18 column (Waters, Milford, USA) on Perista Pump SJ-1211 (Chromatograph ATTO corporations, Tokyo, Japan). The column was washed with deionised water and compounds eluted by using a stepwise gradient ranging from 10 to 70% (v/v) isopropanol in analytical quality water with constant 0.1% TFA (v/v) in solvent system. The gradient was created with 10% increments per 10 min at 2 mL/minute flowrate. The fractions (denoted SPC fractions) were dried by rotary evaporation and tested for antimicrobial activity using the agar-well diffusion assay as described elsewhere.

Active SPC fractions were loaded onto a HiScale column (100 × 16 mm) packed with 15 RPC resin (GE Healthcare, South Africa) fitted to fast protein liquid chromatography (FPLC, ÄKTA purifier, GE Healthcare, South Africa). Fractions were eluted by a linear gradient of 10 to 55% B over 30 min, at a flow rate of 2.5 ml/min (A: analytical quality water containing 0.1%, v/v, TFA; B: HPLC grade acetonitrile containing 0.1%, v/v, TFA). Readings were recorded at 254 nm. Fractions were tested for antibacterial activity against *B. subtilis* subsp. *subtilis* BD170, using the agar-well diffusion assay as described elsewhere.

Fractions with antimicrobial activity collected from the ÄKTA purifier (FPLC active fractions) were lyophilized, resuspended in 50% (v/v) acetonitrile, loaded onto a Discovery BIO Wide Pore C18 HPLC column (10 μm, 250 × 10 mm; Sigma-Aldrich) and eluted by using a linear gradient (25 to 45%) of eluent B over 28 min at a flow rate of 2.0 ml/min. Further separation was on a Surveyor plus HPLC (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Readings were recorded at 254 nm. Peak fractions were collected, dried and the antimicrobial activity tested as described elsewhere.

![Fig. 4](image-url) The UPLC profiles of fraction B collected from C18-HPLC (refer to Fig. 2 b). The top chromatogram (a) shows the base peak intensity mass chromatogram of fraction B and the middle chromatogram (b) the mass extracted chromatogram for the molecular ion with m/z 407.217 at 30 ppm tolerance. The bottom chromatogram (c) shows the spectrophotometric profile at 314 nm and the insert shows the UV spectrum of the peak at 4.23 min.
Fig. 5 ESI-MS and CID spectra (generated via MS² type analysis) of the main component at 4.23 in fraction B, namely xenocoumacin 2. The component mass spectrum of xenocoumacin 2 (structure insert) is shown in the top spectrum (a) and fragmentation product ion spectrum is shown in the bottom spectrum (b). The two main fragments are indicated on the xenocoumacin 2 structure. Refer to the text for the discussion of the fragmentation of xenocoumacin 2.

Fig. 6 Representative CID spectrum over m/z 50–1050 of PAX1 with intact molecular ion at m/z = 1052.79. CID analyses were performed over a CE gradient from 20 to 60 eV at a CV of 15 V. The two structures above the spectrum show the fragments that would lead to the 513.4 and 668.5 product ions and their subsequent fragmentation. The R group for PAX1 is (3R)-3-hydroxy tetradecanoyl and the side-chain of Lys³ links up to the carboxyl group of Lys² to form the ring structure.
Analysis of fractions with ultra-performance liquid chromatography and electrospray ionization mass spectrometry

Fractions with antimicrobial activity collected from the HPLC were subjected to UPLC, using an Aquity UPLC™ linked to a Waters Synapt G2 Mass Spectrometer (Waters Corporation, Milford, USA). This was denoted UPLC-MS. Samples were prepared in 50% acetonitrile in water (1:1, **v/v**) at a concentration 200–1000 μg/mL. Samples were injected at 1–5 μl via Waters Acquity UPLC™ and chromatography was monitored in positive ESI mode and via PDA (230–400 nm). Separation of the components in each HPLC fraction were done on an Acquity UPLC® HSS T3 C18 column (1.8 μm particle size, 2.1 × 150 mm, Waters Corporation, Dublin, Ireland). Chromatography was done with analytical quality water modified with 0.1% (**v/v**) formic acid as eluent A and acetonitrile modified with 0.1% (**v/v**) formic acid as eluent B. The gradient developed at flow rate of 300 μl/min was as follows: 0 to 0.5 min at 40% B, linear gradient from 40 to 95% B from 0.5 to 11 min and 11 to 14 min at 95% B. The rest of the instrument settings for the UPLC-MS mode were as follows: cone voltage set at 15 V, a capillary voltage of 2.5 kV, cone voltage of 15 V, extraction cone voltage 4 V, source temperature of 120 °C, desolvation gas of 650 l/h and desolvation temperature of 275 °C. Data were collected in positive mode by scanning through **m/z** = 100 to 2000 in centroid mode at a rate of 0.2 scans/sec.

High resolution collisionally induced dissociation (CID) analyses were done in the MS² mode (tandem MS or MS/MS) during the UPLC-MS and monitored on a second MS channel. CID were done at a collision energy gradient of 20 to 60 eV at 1 s MS/MS scan time. Data were collected in the second mass analyser (MS2) through **m/z** = 40 to 1500 in centroid mode. The rest of the instrument settings were as described above. To ensure reliable high-resolution MS data, the MS instruments

Fig. 7 UPLC-MS profiles (left panel) and ESI-MS spectra (right panel) of the five major PAX lipopeptides that were detected in the antimicrobial fractions of the X. khoisanae SB10 culture extracts
were calibrated with sodium formate. Single point lock spray using leucine encephalin (m/z = 556.2771) as calibrant was used during analysis to compensate for any m/z drift.

**Antimicrobial activity of fractions from purification**

SPC active fractions were suspended in analytical quality water, containing 0.1% (v/v) TFA to 350 mg/ml. The antimicrobial activity of fractions was tested using an agar-well diffusion assay in a micro well titre plate. In short, the appropriate growth media containing 1.0% (w/v) agar was seeded with a dense 12-h-old culture of *B. subtilis* subsp. *subtilis* BD170, *E. coli* Xen 14 (1.0%, v/v) or *C. albicans* CAB 392 (1.0%, v/v). Wells were made into the agar and 15 μL of each fraction dispensed into a well. Plates were incubated for 24 to 48 h at 37 °C. A clear zone surrounding the well indicated activity. Analytical quality water, containing 0.1% (v/v) TFA, was used as negative control. Ciprofloxacin was used as positive control for *B. subtilis* subsp. *subtilis* BD170 and *E. coli* Xen 14 and amphotericin B for *C. albicans* CAB 392.

**Temperature stability**

SPC active fractions of 350 mg/mL were prepared in MilliQ water, containing 0.1% (v/v) TFA. The suspension was autoclaved for 20 min and tested for antimicrobial activity against *B. subtilis* subsp. *subtilis* BD170, using the agar-well diffusion assay as described elsewhere. Plates were incubated at 37 °C for 24 h. The diameter of growth inhibition zones was recorded and compared to controls. This was done by using the software program ImageJ (v. 1.48).

---

**Additional file**

**Additional file 1:** Detailed mass spectrometric analysis of the chromatographic fractions of *X. khoisanae* extracts. (PDF 471 kb)

---

**Abbreviations**

FPLC: Fast protein liquid chromatography; HPLC: High pressure liquid chromatography; MS: Mass spectrometer/mass spectrometry; NRPS: Non-ribosomal peptide synthetase; PAX: Peptide-antimicrobial-*Xenorhabdus*; TFA: Trifluoroacetic acid; TSB: Tryptic soy broth; TTC: Triphenyl tetrazolium chloride; UPLC: Ultraperformance liquid chromatography

**Acknowledgements**

The authors wish to thank the staff of the LCMS Central Analytical facility at Stellenbosch University for their invaluable assistance in mass spectrometric analyses.

**Authors’ contributions**

JD conducted the experiments; MR analysed the data; EB assisted in data analyses; ADVS, SMD and LMTD supervised the research. All authors contributed to the writing of the paper, and read and approved the final manuscript.

**Funding**

The project was funded by a South African National Research Foundation grant to LMTD with contributions by MR from the BIOPEP Peptide Fund.

**Availability of data and materials**

The datasets generated and/or analysed during the current study are not publicly available due to the preparation of a patent, but are available from the corresponding author (LMTD) on reasonable request.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.
References

1. Thomas GM, Poinar GO. Xenorhabdus gen. nov., a genus of entomopathogenic, nematophilic bacteria of the family Enterobacteriaceae. Int J Syst Bacteriol. 1979;29:352–60.
2. Poinar GO. Biology and taxonomy of Steinernematidae and Heterorhabditidae. In: Gaugler R, Kaya HK, editors. Entomopathogenic nematodes in biological control. Boca Raton: USA: CRC Press; 1990. p. 365.
3. Gótz P, Boman A, Boman HG. Interactions between insect immunity and an insect-pathogenic nematode with symbiotic bacteria. Proc R Soc B Biol Sci. 1981;212:223–33.
4. Dunphy GB, Webster JM. Antimicrobial surface components of Xenorhabdus nematophilus var. dutki and their modification by serum nonimmune lavage of Galleria mellonella. J Invertebr Pathol. 1991;56:480–51.
5. Yang J, Zeng H-M, Lin H-F, Yang X-F, Liu Z, Guo L-H, Yuan J-J, Qiu D-W. An insecticidal protein from Xenorhabdus budapestensis that results in prophenoloxidase activation in the wax moth, Galleria mellonella. J Invertebr Pathol. 2012;106:1–7.
6. Burman M. Xenorhabdus sp. PB30.3. RSC Adv. 2013;3:22072–7.
7. Webster JM, Chen G, Hu K, Li J. Bacterial metabolites. In: Gaugler R, editor. Entomopathogenic nematology. New York: CAB International; 2002. p. 99–114.
8. Durty SR. Insect microbiology. Adv Appl Microbiol. 1959;1:175–200.
9. Paul VJ, Frautschy S, Fenical W, Nealon KH. Antibiotics in microbial ecology. J Chem Ecol. 1981;7:589–97.
10. McInerney BV, Taylor WC, Lacey MJ, Akhurst RJ, Lyons GR, Rhodes SH, Smith DRI, Engelhardt LM, White AH. Biologically active metabolites from Xenorhabdus spp., part 1. Dithiolopyrrolone derivatives with antibiotic activity. J Nat Prod. 1991;54:774–84.
11. Sundar L, Chang FN. Antimicrobial activity and biosynthesis of indole antibiotics produced by Xenorhabdus nematophilus. J Gen Microbiol. 1993;139:313–49.
12. Zhou Q, Grundmann F, Kaiser M, Schiel M, Gaudriault S, Batzer A, Kurz M, Bode HB. Structure and biosynthesis of xenocins from entomopathogenic Xenorhabdus. Chem - A Eur J. 2013;19:16772–83.
13. Bözözményi É, Ersek T, Fodor AM, Fodor AM, Földes LS, Hevesi M, Hogan JS, Katona Z, Klein MG, Kormány A, Pékár S, Szentirmai A, Sztaricskai F, Taylor JS, Rahalison. Identification of a new antimicrobial activity of Xenorhabdus antimicrobics against the plant pathogens Erwinia amylovora and Phytophthora nicotianae. J Appl Microbiol. 2009;107:476–649.
14. Gaultieri M, Aumeelas A, Thaler JO. Identification of a new antimicrobial lipoprotein family from Xenorhabdus nematophilus. J Antibiot (Tokyo). 2009;62:295–302.
15. Klonowicz M, Bouchyluk KAJ, Kahnert AS, Steinhalder D, Gaudriault S, Kaiser M, Bode HB. Characterisation of tenaxillins A–C, natural products from Xenorhabdus indica. Chem - A Eur J. 2014;20:17478–87.
16. Grundmann F, Kaiser M, Kurz M, Schiel M, Batzer A, Bode HB. Structure determination of the bioactive depsipeptide xenobactin from Xenorhabdus sp. PB30.3. RSC Adv. 2013;3:22072–7.
17. Nollmann F, Dowling A, Kaiser M, Deckmann K, Grösch S, French-Constant R, Bode HB. Synthesis of santiameide, a depsipeptide from entomopathogenic Xenorhabdus schemati with activity against Plasmodium falciparum. Bletsttein J Org Chem. 2012;85:28–33.
18. Reinder D, Cowles KN, Proschak A, Nollmann F, Dowling AJ, Kaiser M, French-Constant R, Goodrich-Blair H, Bode HB. Rhabdodeptides as insect-specific virulence factors from entomopathogenic bacteria. ChemBioChem. 2013;14:1991–97.
19. Houard J, Aumeelas A, Noël T, Pages S, Givaudan A, Fittou-Oubahi V, Villain-Guillot P, Gaultieri M. Cabanillasin, a new antifungal metabolite, produced by entomopathogenic Xenorhabdus cabanillasii JMD6. J Antibiot (Tokyo). 2013;66:617–20.
20. Singh J, Banerjee N. Transcriptional analysis and functional characterization of a gene pair encoding iron-regulated xenocin and immunity proteins of Xenorhabdus nematophilus. J Bacteriol. 2008;190:3877–85.
21. Thaler JO, Baghdchian S, Boemoare N. Purification and characterization of xenobactin, a phage tail-like bacteriocin, from the lysogenic strain F1 of Xenorhabdus nematophilus. Appl Environ Microbiol. 1995;61:2049–52.
22. Boemoare NE, Boyer-Giglio MH, Thaler JO, Akhurst RJ, Brethemel M. Xenoycin and bacteriocinogeny in Xenorhabdus nematophilus and other Xenorhabdus spp. Appl Environ Microbiol. 1992;58:3032–7.
23. Fuchs SW, Proschak A, Jaskolla TW, Karas M, Bode HB. Structure elucidation and biosynthesis of lysisin-rich cyclic peptides in Xenorhabdus nematophilus. Org Biomol Chem. 2011;9:3130–2.
24. Malan AP, Kroetz R, Moore SD. Isolation and identification of entomopathogenic nematodes from citrus orchards in South Africa and their biocontrol potential against false codling moth. J Invertebr Pathol. 2011;108:115–25.
25. de Wael JF, Malan AP, Addison MF. Efficacy of entomopathogenic nematodes (Rhabditida: Heterorhabditidae and Steinernematidae) against codling moth, Cydia pomonella (Lepidoptera: Tortricidae) in temperate regions. Biocontrol Sci Tech. 2011;21:1161–76.
26. le Vieux PD, Malan AP. The potential use of entomopathogenic nematodes to control Plasmodium falciparum (Sigmorh) (Hemiptera: Pseudococcidae). South African J Enol Vitic. 2013;34:296–306.
27. Pillay U, Martin LA, Rutherford RS, Berry SD. Entomopathogenic nematodes in sugarcane in South Africa. Proc South African Sugar Technol Assoc. 2009;82:538–41.
28. Malan AP, Mannahlan A. Susceptibility of the Mediterranean fruit fly (Ceratitis capitata) and the Navel fruit fly (Ceratitis rosa) to entomopathogenic nematodes. J Invertebr Pathol. 2009;100:47–9.
29. Webster JM, Li J, Chen G. Indole derivatives with antibacterial and anticymotic properties. US5369668A. 1995. Canada.
30. Gregson RP, McInerney B V, Xencocumins. EP0192731B1. 1991. Australia.
31. Webster JM, Li J, Chen G. Xenomin novel heterocyclic compounds with anticymotic and antineoplastic properties. US5827872A. 1999. Canada.
32. Webster JM, Li J, Chen G. Heterocyclic compounds with antibacterial and anticymotic properties. US6316478B1. 2001. Canada.
33. Rhodes SH, Lyons GR, Gregson RP, Akhurst RJ, Lacey MJ. Xenohbacin antibiotics. WO1984001775A1. 1984. Australia.
34. Gaultieri M, Villain-Guillot P, Givaudan A, Pages S, Cabanillasin, a new antifungal compound, produced by entomopathogenic Xenorhabdus cabanillasii EP2468718A1. 2012. France.
35. Gaultieri M, Villain-Guillot P, Givaudan A, Pages S, Nemacin, an antibiotic produced by entomopathogenic Xenorhabdus cabanillasii WO2012085177A1. 2012. France.
36. Weber T, Bin L, Duddela S, Kug D, Kim HU, Brucollii R, Lee SY, Fischbach MA, Müller R, Wohlleben W, Breitling R, Takano E, Medema MH, AntiSMASH 3.0—a comprehensive resource for the genome mining of biosynthetic gene clusters. Nucleic Acids Res. 2015;43:W237–43.
37. Cinemangic F, Medema MH, Claesen J, Kuittia K, Wieland Brown LC, Mavrommatis K, Pari A, Godfrey PA, Koehrsen M, Gardy J, Biren BW, Takano E, Sali A, Linington RG, Fischbach MA. Insights into secondary metabolism from a global analysis of prokaryotic biosynthetic gene clusters. Cell. 2014;158:412–21.
38. Rautenbach M, Vlok NM, Eyelgh-Beckong HA, Van der Merwe MJ, Stander MA. An electrospray mass spectrometry study on the "in vacuo" hetero-oligomers formed by the antimicrobial peptides, surfactin and granicidin S. J Am Soc Mass Spectrom. 2017;28:1623–37.
39. Dreyer J, Malan AP, Dicks LMT. Three novel Xenorhabdus–Steinernema associations and evidence of strains of Xenorhabdus kboisae switching between different clades. Current Microbiol. 2017;74:938–42.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.